Hims & Hers (NYSE:HIMS) Secures $400M JPMorgan Working Capital Facility

Hims & Hers Health (NYSE: HIMS) unlocked $400 million in working capital through a new uncommitted credit facility arranged with JPMorgan, according to a July 1 report from Yahoo Finance. The facility is designed to give the company financial flexibility as it continues to scale its healthcare and pharmacy operations. Shares gained 8.36% on Wednesday, July 1, 2026, closing at $37.57.

Deal Terms

• Facility size: $400 million in uncommitted working capital through JPMorgan
• Purpose: Supports scaling of healthcare and pharmacy operations, per Yahoo Finance reporting
• Structure: Uncommitted facility, meaning draws are subject to lender discretion at the time of each request
• Filing: Hims & Hers filed an 8-K on July 1, 2026 disclosing a Material Definitive Agreement

Why It Matters

An uncommitted working capital facility of this size gives Hims & Hers an on-demand liquidity tool without the fixed costs of a revolving credit line. Because the facility is uncommitted, JPMorgan retains discretion over whether to fund individual draw requests, which limits the company's guaranteed access but also reduces upfront fees and covenants typically associated with committed revolving facilities.

For a company operating with a net margin of -0.6% and an operating margin of -7.9% on a trailing basis, access to $400 million in potential working capital provides a meaningful buffer as it invests in pharmacy infrastructure and customer acquisition. The facility positions Hims & Hers to manage inventory, fulfillment, and operational costs without immediately diluting shareholders through equity issuances.

Wall Street View

Two analyst actions accompanied the news on July 1. Canaccord Genuity analyst Maria Ripps maintained a Buy rating on Hims & Hers and raised her price target from $32 to $40, the higher of the two revised targets. Bank of America Securities analyst Allen Lutz maintained a Neutral rating and raised his price target from $25 to $36. The broader analyst consensus as of June 1, 2026 stood at 2 Strong Buy, 8 Buy, and 13 Hold ratings, with no Sell or Strong Sell recommendations.

Investor Takeaway

The JPMorgan facility gives Hims & Hers a $400 million liquidity cushion to fund operational scaling without immediate equity dilution, a relevant consideration given current operating losses. With Canaccord's revised $40 price target and BofA's updated $36 target both landing above the July 1 close of $37.57, analyst sentiment on the stock's near-term range is closely split between bullish and neutral camps.